The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Antisense Oligonucleotide Therapies-Global Market Insights and Sales Trends 2024
Synopsis
The global Antisense Oligonucleotide Therapies market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Antisense Oligonucleotide Therapies in various end use industries. The expanding demands from the Genetic Disease, Cancer, Cardiovascular Diseases and Other, are propelling Antisense Oligonucleotide Therapies market. Without GalNAc-conjugated, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the With GalNAc-conjugated segment is estimated at % CAGR for the next seven-year period.
Asia Pacific shows high growth potential for Antisense Oligonucleotide Therapies market, driven by demand from China, the second largest economy with some signs of stabilising, the Antisense Oligonucleotide Therapies market in China is forecast to reach US$ million by 2029, trailing a CAGR of % over the 2023-2029 period, while the U.S. market will reach US$ million by 2029, exhibiting a CAGR of % during the same period.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Antisense Oligonucleotide Therapies, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Antisense Oligonucleotide Therapies market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Antisense Oligonucleotide Therapies market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Antisense Oligonucleotide Therapies sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Antisense Oligonucleotide Therapies covered in this report include Ionis Pharmaceuticals, Sarepta Therapeutics and Nippon Shinyaku, etc.
The global Antisense Oligonucleotide Therapies market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Ionis Pharmaceuticals
Sarepta Therapeutics
Nippon Shinyaku
Global Antisense Oligonucleotide Therapies market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Antisense Oligonucleotide Therapies market, Segment by Type:
Without GalNAc-conjugated
With GalNAc-conjugated
Global Antisense Oligonucleotide Therapies market, by Application
Genetic Disease
Cancer
Cardiovascular Diseases
Other
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Antisense Oligonucleotide Therapies companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
The global Antisense Oligonucleotide Therapies market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Antisense Oligonucleotide Therapies in various end use industries. The expanding demands from the Genetic Disease, Cancer, Cardiovascular Diseases and Other, are propelling Antisense Oligonucleotide Therapies market. Without GalNAc-conjugated, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the With GalNAc-conjugated segment is estimated at % CAGR for the next seven-year period.
Asia Pacific shows high growth potential for Antisense Oligonucleotide Therapies market, driven by demand from China, the second largest economy with some signs of stabilising, the Antisense Oligonucleotide Therapies market in China is forecast to reach US$ million by 2029, trailing a CAGR of % over the 2023-2029 period, while the U.S. market will reach US$ million by 2029, exhibiting a CAGR of % during the same period.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Antisense Oligonucleotide Therapies, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Antisense Oligonucleotide Therapies market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Antisense Oligonucleotide Therapies market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Antisense Oligonucleotide Therapies sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Antisense Oligonucleotide Therapies covered in this report include Ionis Pharmaceuticals, Sarepta Therapeutics and Nippon Shinyaku, etc.
The global Antisense Oligonucleotide Therapies market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Ionis Pharmaceuticals
Sarepta Therapeutics
Nippon Shinyaku
Global Antisense Oligonucleotide Therapies market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Antisense Oligonucleotide Therapies market, Segment by Type:
Without GalNAc-conjugated
With GalNAc-conjugated
Global Antisense Oligonucleotide Therapies market, by Application
Genetic Disease
Cancer
Cardiovascular Diseases
Other
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Antisense Oligonucleotide Therapies companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Antisense Oligonucleotide Therapies
1.1 Antisense Oligonucleotide Therapies Market Overview
1.1.1 Antisense Oligonucleotide Therapies Product Scope
1.1.2 Antisense Oligonucleotide Therapies Market Status and Outlook
1.2 Global Antisense Oligonucleotide Therapies Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Antisense Oligonucleotide Therapies Market Size by Region (2018-2029)
1.4 Global Antisense Oligonucleotide Therapies Historic Market Size by Region (2018-2023)
1.5 Global Antisense Oligonucleotide Therapies Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Antisense Oligonucleotide Therapies Market Size (2018-2029)
1.6.1 North America Antisense Oligonucleotide Therapies Market Size (2018-2029)
1.6.2 Europe Antisense Oligonucleotide Therapies Market Size (2018-2029)
1.6.3 Asia-Pacific Antisense Oligonucleotide Therapies Market Size (2018-2029)
1.6.4 Latin America Antisense Oligonucleotide Therapies Market Size (2018-2029)
1.6.5 Middle East & Africa Antisense Oligonucleotide Therapies Market Size (2018-2029)
2 Antisense Oligonucleotide Therapies Market by Type
2.1 Introduction
2.1.1 Without GalNAc-conjugated
2.1.2 With GalNAc-conjugated
2.2 Global Antisense Oligonucleotide Therapies Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Antisense Oligonucleotide Therapies Historic Market Size by Type (2018-2023)
2.2.2 Global Antisense Oligonucleotide Therapies Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Antisense Oligonucleotide Therapies Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Antisense Oligonucleotide Therapies Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Antisense Oligonucleotide Therapies Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Antisense Oligonucleotide Therapies Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Antisense Oligonucleotide Therapies Revenue Breakdown by Type (2018-2029)
3 Antisense Oligonucleotide Therapies Market Overview by Application
3.1 Introduction
3.1.1 Genetic Disease
3.1.2 Cancer
3.1.3 Cardiovascular Diseases
3.1.4 Other
3.2 Global Antisense Oligonucleotide Therapies Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Antisense Oligonucleotide Therapies Historic Market Size by Application (2018-2023)
3.2.2 Global Antisense Oligonucleotide Therapies Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Antisense Oligonucleotide Therapies Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Antisense Oligonucleotide Therapies Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Antisense Oligonucleotide Therapies Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Antisense Oligonucleotide Therapies Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Antisense Oligonucleotide Therapies Revenue Breakdown by Application (2018-2029)
4 Antisense Oligonucleotide Therapies Competition Analysis by Players
4.1 Global Antisense Oligonucleotide Therapies Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Antisense Oligonucleotide Therapies as of 2022)
4.3 Date of Key Players Enter into Antisense Oligonucleotide Therapies Market
4.4 Global Top Players Antisense Oligonucleotide Therapies Headquarters and Area Served
4.5 Key Players Antisense Oligonucleotide Therapies Product Solution and Service
4.6 Competitive Status
4.6.1 Antisense Oligonucleotide Therapies Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Ionis Pharmaceuticals
5.1.1 Ionis Pharmaceuticals Profile
5.1.2 Ionis Pharmaceuticals Main Business
5.1.3 Ionis Pharmaceuticals Antisense Oligonucleotide Therapies Products, Services and Solutions
5.1.4 Ionis Pharmaceuticals Antisense Oligonucleotide Therapies Revenue (US$ Million) & (2018-2023)
5.1.5 Ionis Pharmaceuticals Recent Developments
5.2 Sarepta Therapeutics
5.2.1 Sarepta Therapeutics Profile
5.2.2 Sarepta Therapeutics Main Business
5.2.3 Sarepta Therapeutics Antisense Oligonucleotide Therapies Products, Services and Solutions
5.2.4 Sarepta Therapeutics Antisense Oligonucleotide Therapies Revenue (US$ Million) & (2018-2023)
5.2.5 Sarepta Therapeutics Recent Developments
5.3 Nippon Shinyaku
5.3.1 Nippon Shinyaku Profile
5.3.2 Nippon Shinyaku Main Business
5.3.3 Nippon Shinyaku Antisense Oligonucleotide Therapies Products, Services and Solutions
5.3.4 Nippon Shinyaku Antisense Oligonucleotide Therapies Revenue (US$ Million) & (2018-2023)
5.3.5 Recent Developments
6 North America
6.1 North America Antisense Oligonucleotide Therapies Market Size by Country (2018-2029)
6.2 United States
6.3 Canada
7 Europe
7.1 Europe Antisense Oligonucleotide Therapies Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Antisense Oligonucleotide Therapies Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Antisense Oligonucleotide Therapies Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Antisense Oligonucleotide Therapies Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Antisense Oligonucleotide Therapies Market Dynamics
11.1 Antisense Oligonucleotide Therapies Industry Trends
11.2 Antisense Oligonucleotide Therapies Market Drivers
11.3 Antisense Oligonucleotide Therapies Market Challenges
11.4 Antisense Oligonucleotide Therapies Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
